# Phase 14 - answer quality, before and after

- generated_by: `run_phase14_answer_review.py` (phase14.3.3-1.0)
- created_at: 2026-10-08T17:10:59+00:00
- questions reviewed: 1

Both sides ran the same retrieval against the same index. Nothing was re-embedded, no weight was changed, and no model graded anything here - every number below is a count over the answer text, from `scripts/answer_quality.py`.

**How to read "marked closing conclusion".** It counts a closing line that opens with a synthesis marker. It is NOT the same as "the answer reaches a conclusion": the prompt asks for the conclusion in the TAKEAWAY, and an answer that puts it there and then adds a closing line as well is repeating itself. A low count here is a reason to read the takeaways, not evidence that the answers only transcribe.

## The corpus, in numbers

| measure | before | after | change |
|---|---|---|---|
| Mean words, whole answer | 1077.0 | 434.0 | -643.0  ✓ |
| Mean words, Direct Answer | 422.0 | 195.0 | -227.0  ✓ |
| Mean words, sections 2-6 | 637.0 | 221.0 | -416.0  ✓ |
| Mean claims in Direct Answer | 9.0 | 3.0 | -6.0 |
| Mean repetition in Direct Answer | 0.0 | 0.0 | same |
| Answers opening with boilerplate | 0 | 0 | same |
| Answers with a marked closing conclusion | 0 | 1 | +1  ✓ |
|   of those, conclusions CITED | 0 | 1 | +1  ✓ |
|   of those, conclusions UNCITED | 0 | 0 | same |
| Answers saying what changed | 0 | 0 | same |
| Answers naming a publisher | 0 | 0 | same |
| Substantive answers in the 100-220 word band | 0 | 1 | +1  ✓ |
| Uncited claims across the corpus | 0 | 0 | same |
| Direct Answers over 220 words | 1 | 0 | -1  ✓ |
| Unsupported answers over 80 words (whole answer) | 0 | 0 | same |
| Mean words, unsupported answers (whole answer) | 0 | 0 | same |
| Answers whose generation did not finish | 0 | 0 | same |

A tick marks a measure that moved the way the phase intended. It is a direction, not a proof: the only claims of improvement in this report are the ones labelled IMPROVED below, each of which has a deterministic rule behind it.

Verdicts across all questions: **2 IMPROVED**, 1 CHANGED, **0 REGRESSED**.

## Question by question

### AMZN - risk_or_credit

**What risks does the research identify for Amazon around capital expenditure, competition and regulation?**

| | before | after |
|---|---|---|
| words (Direct Answer) | 422 | 195 |
| words (whole answer) | 1077 | 434 |
| citations used | 1,2,3,4,5,6,7,8 | 1,2,3,5,6,7 |
| confidence | Medium | Medium |
| documents selected | 8 | 8 |
| source set identical | yes | |

Observed changes:

- **CHANGED** - shorter by 227 words, but citations fell from 8 to 6 - shorter is not better if evidence went with it
- **IMPROVED** - moved into the 100-220 word band
- **IMPROVED** - added a cited conclusion where there was none: "Taken together, these sources point to a tension between aggressive capex and financing needs and external pre"

<details><summary>before</summary>

```
## 1. Direct Answer
- Capital expenditure (capex) risks:
  - Research notes flag materially higher capex (the company disclosed a ~$200bn FY26 capex program) that reduced free cash flow and prompted investor concern about whether the investments will “pay off,” with analysts asking for more justification that the spending will not “consume all of the company’s cash flow every year into perpetuity” [5].  
  - Sell‑side research lists “higher‑than‑expected capital intensity for either the e‑commerce platform or AWS” as a risk that “could weigh on our free cash flow projections” [2][4].  
  - Deutsche Bank describes the company’s large FY26 capex plan (~$200bn) and documents significant 2026 debt and liquidity activity used to fund capex (roughly $92bn–$93bn of completed debt financings in 2026 and access to a $17.5bn delayed‑draw facility), noting these funding actions in the context of the elevated AI infrastructure investment cycle [1].  
  - A sell‑side note also highlights that “continued investment spending” may negatively affect overall margins and lists investment spending as a company risk [3].

- Competition risks:
  - Company filings and annual reports state Amazon “faces intense competition” across many businesses and geographies, with competitors that “may secure better terms from vendors, adopt more aggressive pricing, and devote more resources to technology, infrastructure, fulfillment, and marketing” [7][8].  
  - Sell‑side research flags “rise in competitive intensity” and “market share losses given the competitive eCommerce environment” and specifically cites share losses to brick‑and‑mortar retailers and other online competitors as investment risks [2][3][4].

- Regulation and legal risks:
  - Amazon’s 10‑K warns that “Government Regulation Is Evolving and Unfavorable Changes Could Harm Our Business,” describing a broad set of regulatory areas (taxation, privacy, data use/protection, competition, consumer protection, etc.) and noting regulatory uncertainty and a growing patchwork of laws that could increase compliance costs or require materially adverse business changes [6].  
  - The 10‑K further reports the company is “regularly subject to formal and informal reviews, investigations, and other proceedings” including “open investigations based on claims that aspects of our operations infringe competition‑related or consumer protection rules or regulations,” and states that unfavorable regulatory actions “could cause us to incur substantial costs, expose us to ... penalties, diminish demand or availability of our products and services, increase our cost of doing business, require us to change our business practices … or otherwise have a material effect on our operations” [6].  
  - Annual report and other company materials reiterate that regulatory and political scrutiny is increasing and that competitors and new entrants may change the competitive and regulatory landscape [7][8].

## 2. Evidence Used
- [1] Deutsche_Bank 7.27.26 research note — used for details on the ~$200bn FY26 capex plan, Deutsche Bank’s 2027 capex commentary, and the description of 2026 debt issuances and liquidity items supporting capex [1].  
- [5] GimmeCredit 2.6.26 credit note — used for the $200bn capex figure, observed free cash flow decline (from $33bn to $8bn) tied to higher capex, and investor/analyst concern language about reassurance on returns [5].  
- [2] UBS 4.29.26 research note — used for UBS’s explicit valuation risk listing that includes “rise in competitive intensity” and “higher‑than‑expected capital intensity” as valuation risks [2].  
- [4] UBS 2.3.26 research note — used for UBS’s risk statement reiterating “higher than expected capital intensity” as a valuation risk [4].  
- [3] Citizens 2.1.26 research note — used for the list of investment risks including “market share losses,” “share losses to brick‑and‑mortar retailers,” and “continued investment spending and the impact to overall margins” [3].  
- [6] AMZN 10‑K (2.5.26) — used for the company’s disclosure on evolving regulation, regulatory investigations (including competition/consumer protection), and potential adverse outcomes from unfavorable regulation [6].  
- [7] AMZN ARS 4.10.26 company material — used for company risk factor language about facing “intense competition” across businesses and geographies [7].  
- [8] AMZN Annual Report 2025 (4.9.26) — used for similar company risk factor language on competition and regulatory scrutiny [8].

## 3. Source Citations
- [1] AMZN Deutsche_Bank 7.27.26.pdf, pages 5–8.  
- [2] AMZN UBS 4.29.26.pdf, pages 4–6.  
- [3] AMZN Citizens 2.1.26.pdf, pages 6–7.  
- [4] AMZN UBS 2.3.26.pdf, pages 13–15.  
- [5] AMZN GimmeCredit 2.6.26 Credit.pdf, pages 1–1.  
- [6] AMZN 10K 2.5.26.pdf, pages 15–15.  
- [7] AMZN ARS 4.10.26.pdf, pages 16–17.  
- [8] AMZN Annual Report 2025 4.9.26.pdf, pages 16–17.

## 4. Evidence Limitations
- The sell‑side research excerpts list risks but generally do not quantify probabilities or provide modeled impacts for capex, competition, or regulation, limiting assessment of magnitude or likelihood [2][4][1][5].  
- Some research chunks are excerpts/truncated (for example the UBS and Citizens chunks), so full context and any additional qualifying language in those reports are not available in the retrieved text [2][3][4].  
- The company filings and annual report describe broad regulatory and investigative risk areas but the retrieved excerpts do not include specifics on active investigations, timelines, or potential financial exposure amounts, so the precise regulatory liabilities are not detailed here [6][7][8].  
- The evidence pack mixes sell‑side views and company disclosures; sell‑side notes reflect analyst opinion rather than company statements, and the pack contains only partial slices of those analyst reports, limiting completeness [2][4][1].

## 5. Needs Human Review
- Verify full capex figures, timing, and assumptions in the original Deutsche Bank and GimmeCredit reports to confirm the $200bn FY26 figure and any 2027 estimates referenced (Deutsche Bank’s commentary on 2027 capex near ~$300bn) [1][5].  
- Confirm the free cash flow amounts and the year‑over‑year change (GimmeCredit reports free cash flow of $8bn vs $33bn prior year) in the underlying filings or full credit note for accuracy and context [5].  
- Review the complete UBS, Citizens, and Deutsche Bank research notes for any additional nuance, sensitivity analysis, or mitigating factors not present in the excerpts [2][3][4][1].  
- Inspect the full 10‑K and annual report sections on investigations and risk factors for specifics on open investigations, potential penalties, and any disclosed contingency estimates or legal reserve amounts [6][7][8].  
- Confirm which statements in the sell‑side research reflect analyst forecasts versus company‑provided guidance or management commentary by checking the original reports and the company transcripts/filings [1][2][4][5].

## 6. Confidence
Medium — multiple sell‑side research notes and company filings in the retrieved set consistently identify elevated capex (including a disclosed ~$200bn FY26 program), intensified competition across businesses, and broad evolving regulatory/legal risks, but the excerpts are partial and lack quantified likelihoods or detailed regulatory exposure information [1][5][2][6].
```

</details>

<details><summary>after</summary>

```
## Automated checks flagged this answer

- 2 supplied chunk(s) were never cited - the evidence pack was wider than the answer used

_These are deterministic checks on the generated text. Nothing was rewritten - read the answer with these in mind._

---

## 1. Direct Answer
Capital-expenditure risk: sell‑side and credit research flag higher‑than‑expected capital intensity and the scale of AMZN’s AI/AWS capex as a risk, and Deutsche Bank documents AMZN’s ~\$200bn FY26 capex plan alongside roughly \$92bn–\$93bn of 2026 debt financings and access to a further \$17.5bn facility [2][1][5]. (Gimme Credit notes the \$200 billion 2026 plan reduced free cash flow to \$8 billion from \$33 billion in 2024 and reports analysts sought reassurance that the investments will “pay off” [5].)  
Competition risk: the company’s public filings state “We Face Intense Competition,” and sell‑side notes list market‑share losses and a rise in competitive intensity (online and offline) as valuation and operating risks [7][3][2].  
Regulatory risk: the company’s 10‑K warns that evolving and expanding regulation and active investigations (including competition/antitrust and data/privacy areas) “could cause us to incur substantial costs” or otherwise have a material adverse effect on operations [6].  
Taken together, these sources point to a tension between aggressive capex and financing needs and external pressures from competition and regulation that could compress cash flow or require adverse business changes [1][5][2][7][6].

## 2. Evidence Used
- Deutsche Bank research: documented FY26 capex plan and 2026 funding activity [1].  
- UBS research: flagged higher‑than‑expected capital intensity and rise in competitive intensity as risks [2].  
- Citizens research: noted market‑share and investment/margin risks [3].  
- Gimme Credit note: detailed \$200bn 2026 capex, FCF impact, and analyst reactions [5].  
- 2026 Form 10‑K (SEC filing): described evolving regulation, investigations, and legal/regulatory risks [6].  
- Company Annual Report/ARS: stated “We Face Intense Competition” and competitive pressures [7].

## 3. Source Citations
[1] AMZN Deutsche_Bank 7.27.26.pdf p.5-8  
[2] AMZN UBS 4.29.26.pdf p.4-6  
[3] AMZN Citizens 2.1.26.pdf p.6-7  
[5] AMZN GimmeCredit 2.6.26 Credit.pdf p.1-1  
[6] AMZN 10K 2.5.26.pdf p.15-15  
[7] AMZN ARS 4.10.26.pdf p.16-17

## 4. Evidence Limitations
- The pack does not include detailed scenario analysis of long‑term returns on the incremental capex (ROI timelines) beyond headline cash‑flow figures.  
- The documents do not provide outcomes, fines, or quantified exposures for ongoing regulatory investigations.

## 5. Needs Human Review
- Verify any more recent company disclosures, earnings‑call commentary, or filings after these documents for updates on capex plans, financing, or regulatory developments.  
- Confirm current status and potential financial impact of specific regulatory investigations or lawsuits referenced in the 10‑K.

## 6. Confidence
High — multiple company filings (10‑K/Annual Report) and several analyst/credit research notes in the pack explicitly identify capex scale/funding, competitive intensity, and evolving regulatory/investigation risks that support the answer [1][5][2][7][6][3].
```

</details>
